This promotional website is for UK healthcare professionals involved in the care of patients with cancer. Adverse event reporting information can be found below.
UK-VNCCLL-230003. Date of Preparation: March 2023.
On demand: CLL treatment sequencing content post EHA 2023
On demand: Access content from BSH 2023
Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk.
Adverse events should also be reported to AbbVie on [email protected]
You are strongly advised to read the prescribing information and summary of product characteristics to evaluate patient suitability for Venclyxto.
UK-VNCCLL-230369. Date of preparation: November 2023